Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0AZLBZ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
LY4052031
|
|||||
| Synonyms |
LY4052031
Click to Show/Hide
|
|||||
| Organization |
Eli Lilly (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Antibody Name |
Anti-Nectin-4 IgG1 Fc-silent mAb
|
Antibody Info | ||||
| Antigen Name |
Nectin-4 (NECTIN4)
|
Antigen Info | ||||
| Payload Name |
LSN3889710
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
A cleavable peptide linker
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Breast cancer |
1 Trials
|
||||||||
| Cervical cancer |
1 Trials
|
||||||||
| Head and neck cancer |
1 Trials
|
||||||||
| Kidney cancer |
1 Trials
|
||||||||
| Lung cancer |
1 Trials
|
||||||||
| Oesophageal cancer |
1 Trials
|
||||||||
| Ovarian cancer |
1 Trials
|
||||||||
| Pancreatic cancer |
1 Trials
|
||||||||
| Prostate cancer |
1 Trials
|
||||||||
| Urothelial cancer |
1 Trials
|
ADC-specific functional property(2027 Update)
Bystander Killing Effect
| Bystander Killing Effect | Description | Reference |
|---|---|---|
| yes |
Additionally, bystander activity exerted by LY4052031 on antigen negative cells co-cultured with antigen positive cells was greater than that observed with the clinical benchmark enfortumab vedotin-ejfv.
Click to Show/Hide
|
[1]
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
Eligible participants include those with specific solid tumors (separate cohort requirements apply), ECOG 0-1, and adequate tumor tissue availability. Major exclusions include uncontrolled CNS metastases, cardiovascular disease, severe prior toxicities, QTcF ≥470 ms, and active corneal/pulmonary conditions, with additional enfortumab vedotin-related restrictions for certain cohorts.
Click to Show/Hide
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06465069 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors | ||||
| Primary Endpoint |
Phase 1a aims to determine the Recommended Phase 2 Dose (RP2D) of LY4052031 by evaluating dose-limiting toxicities (DLTs) within Cycle 1 (21 days). Phase 1b assesses antitumor activity through Overall Response Rate (ORR) per RECIST 1.1 over approximately 48 months.
|
||||
| Other Endpoint |
Key evaluations include pharmacokinetics (PK) parameters (Cmin, AUC) during Cycle 1 and antitumor activity metrics (ORR, DOR, TTR, PFS, DCR, OS) per RECIST 1.1 tracked over 48 months to comprehensively characterize LY4052031's clinical profile.
|
||||
References